SEARCH

SEARCH BY CITATION

References

  • 1
    Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2007. Global strategy for the diagnosis, management and prevention of COPD. Available from: http://www.goldcopd.org[Accessed August 1, 2009].
  • 2
    Calverley PM, Georgopopoulous D. Chronic obstructive pulmonary disease: symptoms and signs. Eur Respir Mon 2006;38:723.
  • 3
    Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences—clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:23556.
  • 4
    Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003;41(Suppl.):46s53s.
  • 5
    Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(Suppl. 2):398S401S.
  • 6
    Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009;4:24551.
  • 7
    Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:5026.
  • 8
    Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:141822.
  • 9
    Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD—a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009;4:20323.
  • 10
    Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008;133:3441.
  • 11
    Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis 2008;3:110.
  • 12
    Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:154354.
  • 13
    Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004;24:20610.
  • 14
    Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:95364.
  • 15
    Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:122438.
  • 16
    Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:41669.
  • 17
    Rennard S, Leidy NK. Definition and severity of COPD exacerbations. In: WedzichaW, MartinezF, eds. Exacerbations of Chronic Obstructive Pulmonary Disease (COPD). New York: Informa Healthcare, 2009.
  • 18
    Calverley P, Pauwels R, Loefdahl C-G, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005;26:40613.
  • 19
    Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396401.
  • 20
    Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:120413. discussion 1213-1205.
  • 21
    Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:93246.
  • 22
    Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:160813.
  • 23
    Woolhouse IS, Hill SL, Stockley RA. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 2001;56:94753.
  • 24
    Food and Drug Administration. Draft guidance for industry on acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease: developing antimicrobial drugs for treatment; availability. Fed Regist 2008;73:496845. Available from: http://www.access.gpo.gov/su_docs/fedreg/a080822c.html[Accessed December, 2006.
  • 25
    Nunnally J, Bernstein I. Psychometric Theory (3rd ed.). New York: McGraw Hill, 1994.
  • 26
    Rothman M, Burke L, Erickson P, et al. Use of existing PRO instruments and their modification: good research practices for evaluating and documenting content validity. Value Health 2009;12:107583.
  • 27
    Cresswell J. Qualitative Inquiry and Research Design: Choosing Among Five Traditions. Thousand Oaks, CA: Sage Publications, 1997.
  • 28
    Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 2008;26:36370.
  • 29
    Marshall C, Rossman G. Designing Qualitative Research (2nd ed.). Newbury Park: Sage, 1995.
  • 30
    Adams R, Chavannes N, Jones K, et al. Exacerbations of chronic obstructive pulmonary disease—a patients’ perspective. Prim Care Respir J 2006;15:1029.
  • 31
    Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006;130:13342.
  • 32
    Nicolson P, Anderson P. The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:2532.
  • 33
    Starks H, Trinidad SB. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res 2007;17:137280.
  • 34
    Blumer H. Symbolic Interactionism. Berkeley, CA: University of California Press, 1986.
  • 35
    Dey I. Grounding Grounded Theory: Guidelines for Qualitative Inquiry. San Diego, CA: Academic Press, 1999.
  • 36
    Sokolowski R. Introduction to Phenomenology. Cambridge: Cambridge University Press, 2000.
  • 37
    Stewart D, Mickunas A. Exploring Phenomenology: A Guide to the Field and Its Literature. Chicago: American Library Association, 1974.
  • 38
    Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax, CA 1999;54:5816.
  • 39
    Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:25766.
  • 40
    Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:13217.
  • 41
    Stone AA, Broderick JE, Porter LS, Kaell AT. The experience of rheumatoid arthritis pain and fatigue: examining momentary reports and correlates over one week. Arthritis Care Res 1997;10:18593.
  • 42
    Broderick JE, Schwartz JE, Vikingstad G, et al. The accuracy of pain and fatigue items across different reporting periods. Pain 2008;139:14657.
  • 43
    Dale O, Hagen KB. Despite technical problems personal digital assistants outperform pen and paper when collecting patient diary data. J Clin Epidemiol 2007;60:817.
  • 44
    Tiplady B, Crompton GK, Dewar MH, et al. The use of electronic diaries in respiratory studies. Drug Inf J 1997;31:75964.
  • 45
    Palermo TM, Valenzuela D, Stork PP. A randomized trial of electronic versus paper pain diaries in children: impact on compliance, accuracy, and acceptability. Pain 2004;107:2139.
  • 46
    McKenzie S, Paty J, Grogan D, et al. Proving the eDiary dividend. Appl Clin Trials 2004;13:5468.
  • 47
    Morren M, Van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary pain measurement using electronic diaries: a systematic review. Eur J Pain 2009;13:35465.
  • 48
    Stone AA, Shiffman S, Schwartz JE, et al. Patient non-compliance with paper diaries. BMJ 2002;324:11934.
  • 49
    Palmblad M, Tiplady B. Electronic diaries and questionnaires: designing user interfaces that are easy for all patients to use. Qual Life Res 2004;13:1199207.